These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 16400244)

  • 21. New understanding of mechanisms of action of bipolar medications.
    Sanacora G
    J Clin Psychiatry; 2008; 69 Suppl 5():22-7. PubMed ID: 19265637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
    Nierenberg AA; Ostacher MJ; Calabrese JR; Ketter TA; Marangell LB; Miklowitz DJ; Miyahara S; Bauer MS; Thase ME; Wisniewski SR; Sachs GS
    Am J Psychiatry; 2006 Feb; 163(2):210-6. PubMed ID: 16449473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A brief history of the development of antidepressant drugs: from monoamines to glutamate.
    Hillhouse TM; Porter JH
    Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders.
    de Sousa RT; Loch AA; Carvalho AF; Brunoni AR; Haddad MR; Henter ID; Zarate CA; Machado-Vieira R
    Neuropsychopharmacology; 2017 Mar; 42(4):787-800. PubMed ID: 27510426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of glutamate in anxiety and related disorders.
    Cortese BM; Phan KL
    CNS Spectr; 2005 Oct; 10(10):820-30. PubMed ID: 16400245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.
    Brennan BP; Hudson JI; Jensen JE; McCarthy J; Roberts JL; Prescot AP; Cohen BM; Pope HG; Renshaw PF; Ongür D
    Neuropsychopharmacology; 2010 Feb; 35(3):834-46. PubMed ID: 19956089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glutamate modulators as novel interventions for mood disorders.
    Mathew SJ; Keegan K; Smith L
    Braz J Psychiatry; 2005 Sep; 27(3):243-8. PubMed ID: 16224615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders.
    Ketter TA; Manji HK; Post RM
    J Clin Psychopharmacol; 2003 Oct; 23(5):484-95. PubMed ID: 14520126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression.
    Choudary PV; Molnar M; Evans SJ; Tomita H; Li JZ; Vawter MP; Myers RM; Bunney WE; Akil H; Watson SJ; Jones EG
    Proc Natl Acad Sci U S A; 2005 Oct; 102(43):15653-8. PubMed ID: 16230605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synaptic P2X7 receptor regenerative-loop hypothesis for depression.
    Bennett MR
    Aust N Z J Psychiatry; 2007 Jul; 41(7):563-71. PubMed ID: 17558618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lamotrigine in the treatment of bipolar disorder.
    Bhagwagar Z; Goodwin GM
    Expert Opin Pharmacother; 2005 Jul; 6(8):1401-8. PubMed ID: 16013989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
    Solmi M; Veronese N; Zaninotto L; van der Loos ML; Gao K; Schaffer A; Reis C; Normann C; Anghelescu IG; Correll CU
    CNS Spectr; 2016 Oct; 21(5):403-418. PubMed ID: 27686028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Glutamatergic conception of mood disorders].
    Permoda-Osip A; Rybakowski J
    Psychiatr Pol; 2011; 45(6):875-88. PubMed ID: 22335130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine.
    Singh J; Zarate CA; Krystal AD
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):227-8. PubMed ID: 14722708
    [No Abstract]   [Full Text] [Related]  

  • 35. Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study.
    Yoon SJ; Lyoo IK; Haws C; Kim TS; Cohen BM; Renshaw PF
    Neuropsychopharmacology; 2009 Jun; 34(7):1810-8. PubMed ID: 19194376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased anterior cingulate/medial prefrontal cortical glutamate and creatine in bipolar depression.
    Frye MA; Watzl J; Banakar S; O'Neill J; Mintz J; Davanzo P; Fischer J; Chirichigno JW; Ventura J; Elman S; Tsuang J; Walot I; Thomas MA
    Neuropsychopharmacology; 2007 Dec; 32(12):2490-9. PubMed ID: 17429412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glutamate and the glutamate receptor system: a target for drug action.
    Bleich S; Römer K; Wiltfang J; Kornhuber J
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S33-40. PubMed ID: 12973748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.
    Yüksel C; Öngür D
    Biol Psychiatry; 2010 Nov; 68(9):785-94. PubMed ID: 20728076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered glial plasticity in animal models for mood disorders.
    Czéh B; Fuchs E; Flügge G
    Curr Drug Targets; 2013 Oct; 14(11):1249-61. PubMed ID: 23597041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.